1. significant infection or other acute illness, including fever \>100°f (\>37.8°c) on the day prior to or day of randomization. 2. history of laboratory-confirmed sars-cov-2 infection or any positive sars-cov-2 result based on available data at screening. 3. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 4. known history of allergy or reaction to any component of the study drug formulation. 5. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 6. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. 7. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. 8. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 9. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study 10. currently pregnant or breastfeeding. 11. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 12. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program,, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 13. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded. sub-study exclusion criteria are as follows: 1. patient have received a covid-19 vaccination ≤ 14 days before sub-study day1 or plan to receive a covid-19 vaccination ≤ 14 days after sub-study day1. (such participants can subsequently be included in the study once they have reached \>14 days after their last dose of vaccine). 2. patient have two or more untreated cardiac risk factors or suspected unstable cardiac disease. 3. judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

1. significant infection or other acute illness, including fever \>100°f (\>37.8°c) on the day prior to or day of randomization. 2. history of laboratory-confirmed sars-cov-2 infection or any positive sars-cov-2 result based on available data at screening. 3. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 4. known history of allergy or reaction to any component of the study drug formulation. 5. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 6. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. 7. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. 8. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 9. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study 10. currently pregnant or breastfeeding. 11. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 12. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program,, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 13. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded. sub-study exclusion criteria are as follows: 1. patient have received a covid-19 vaccination ≤ 14 days before sub-study day1 or plan to receive a covid-19 vaccination ≤ 14 days after sub-study day1. (such participants can subsequently be included in the study once they have reached \>14 days after their last dose of vaccine). 2. patient have two or more untreated cardiac risk factors or suspected unstable cardiac disease. 3. judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

significant infection or other acute illness, including fever >100°f (>37.8°c) on the day prior to or day of randomization. history of laboratory-confirmed sars-cov-2 infection or any positive sars-cov-2 result based on available data at screening. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). known history of allergy or reaction to any component of the study drug formulation. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study currently pregnant or breastfeeding. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program,, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded. sub-study exclusion criteria are as follows: patient have received a covid-19 vaccination ≤ 14 days before sub-study day1 or plan to receive a covid-19 vaccination ≤ 14 days after sub-study day1. (such participants can subsequently be included in the study once they have reached >14 days after their last dose of vaccine). patient have two or more untreated cardiac risk factors or suspected unstable cardiac disease. judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

significant infection or other acute illness, including fever >100°f (>37.8°c) on the day prior to or day of randomization. history of laboratory-confirmed sars-cov-2 infection or any positive sars-cov-2 result based on available data at screening. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). known history of allergy or reaction to any component of the study drug formulation. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study currently pregnant or breastfeeding. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program,, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded. sub-study exclusion criteria are as follows: patient have received a covid-19 vaccination ≤ 14 days before sub-study day1 or plan to receive a covid-19 vaccination ≤ 14 days after sub-study day1. (such participants can subsequently be included in the study once they have reached >14 days after their last dose of vaccine). patient have two or more untreated cardiac risk factors or suspected unstable cardiac disease. judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

significant infection or other acute illness, including fever >100°f (>37.8°c) on the day prior to or day of randomization. history of laboratory-confirmed sars-cov-2 infection or any positive sars-cov-2 result based on available data at screening. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). known history of allergy or reaction to any component of the study drug formulation. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study currently pregnant or breastfeeding. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program,, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

significant infection or other acute illness, including fever >100°f (>37.8°c) on the day prior to or day of randomization. history of laboratory-confirmed sars-cov-2 infection or any positive sars-cov-2 result based on available data at screening. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). known history of allergy or reaction to any component of the study drug formulation. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study currently pregnant or breastfeeding. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program,, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

1. significant infection or other acute illness, including fever >100°f (>37.8°c) on the day prior to or day of randomization. 2. history of laboratory-confirmed sars-cov-2 infection or any positive sars-cov-2 result based on available data at screening. 3. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 4. known history of allergy or reaction to any component of the study drug formulation. 5. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 6. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. 7. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. 8. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 9. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study 10. currently pregnant or breastfeeding. 11. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 12. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program,, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 13. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

1. significant infection or other acute illness, including fever >100°f (>37.8°c) on the day prior to or day of randomization. 2. history of laboratory-confirmed sars-cov-2 infection or any positive sars-cov-2 result based on available data at screening. 3. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 4. known history of allergy or reaction to any component of the study drug formulation. 5. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 6. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. 7. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. 8. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 9. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study 10. currently pregnant or breastfeeding. 11. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 12. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program,, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 13. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

1. significant infection or other acute illness, including fever >100°f (>37.8°c) on the day prior to or day of randomization. 2. history of laboratory-confirmed sars-cov-2 infection. 3. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 4. known history of allergy or reaction to any component of the study drug formulation. 5. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 6. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. 7. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. 8. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 9. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study 10. currently pregnant or breastfeeding. 11. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 12. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program,, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 13. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

1. significant infection or other acute illness, including fever >100°f (>37.8°c) on the day prior to or day of randomization. 2. history of laboratory-confirmed sars-cov-2 infection. 3. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 4. known history of allergy or reaction to any component of the study drug formulation. 5. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 6. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. 7. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. 8. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 9. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study 10. currently pregnant or breastfeeding. 11. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 12. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program,, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 13. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

1. significant infection or other acute illness, including fever >100°f (>37.8°c) on the day prior to or day of randomization. 2. history of laboratory-confirmed sars-cov-2 infection. 3. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 4. known history of allergy or reaction to any component of the study drug formulation. 5. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 6. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. 7. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. 8. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 9. prior/concomitant therapy 10. receipt of blood products or immunoglobulins, including mabs, within 6 months, or 5 antibody half-lives if longer than 6 months, prior to screening 11. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study 12. currently pregnant or breastfeeding. 13. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 14. employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.

1. significant infection or other acute illness, including fever >100°f (>37.8°c) on the day prior to or day of randomization. 2. history of laboratory-confirmed sars-cov-2 infection. 3. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 4. known history of allergy or reaction to any component of the study drug formulation. 5. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 6. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow-up. 7. bleeding disorder or prior history of significant bleeding or bruising following im injections or venepuncture. 8. any other significant disease, disorder, or finding. that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 9. prior/concomitant therapy 10. receipt of blood products or immunoglobulins, including mabs, within 6 months, or 5 antibody half-lives if longer than 6 months, prior to screening 11. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study 12. currently pregnant or breastfeeding. 13. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 14. employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.